Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31

Trial Status

Terminated1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT01203228Phase 3Terminated
Dose-reduced Versus Standard Conditioning in MDS/sAML
Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia
Principalinvestigator

Research Network

Collaboration Network

18 collaborators·64 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Univ Hospital Kiel - Germany

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Tapan M Kadia

M.D. Anderson Cancer Center

Moderately Similar
13 trials

Shared therapeutic areas:

Secondary Acute Myeloid LeukemiaMyelodysplastic Syndromes
Similarity Score30%

Domink Heim, Prof.

University Hospital, Basel, Switzerland

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Marie Robin, MD

Hopital Saint-Louis Paris, France

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Gerhard Behre

Martin-Luther-Universitaet Halle-Wittenberg - Germany

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Stefano Guidi, MD

Careggi Hospital - Florence, Italy

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Kathrin Haifa Al-Ali, MD

University Hospital Leipzig, Germany

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Liisa Volin, MD

Helsinki University Central Hospital, Finland

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Augustin Ferrant, MD

Cliniques Universitaires St. Luc Bruxelles, Belgium

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Allione Bernardino

Santi Antonio E Biagio

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Nicolaus Kröger, MD

Universitätsklinikum Hamburg-Eppendorf

Related
1 trials

Shared therapeutic areas:

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia

Worked with same sponsors:

European Society for Blood and Marrow TransplantationPierre Fabre Medicament
Collaborated on 1 trial
Similarity Score24%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT01203228Phase 3PrincipalInvestigator

Dose-reduced Versus Standard Conditioning in MDS/sAML

Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia
Terminated

All 1 trials loaded